Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: Permeability and pharmacokinetic study

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 3, 2012, Pages 514-523

  Zabaleta, Virginia ^a   Ponchel, Gilles ^b,c   Salman, Hesham ^a   Agüeros, Maite ^a   Vauthier, Christine ^b,c   Irache, Juan M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CNRS   (France)

Author keywords

Bioadhesion; Drug delivery; Nanoparticles; Oral; Paclitaxel; Poly(ethylene glycol)

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CYTOCHROME P450; DOCETAXEL; DRUG CARRIER; GANTREZ; GANTREZ COPOLYMER; GLYCOPROTEIN P; MACROGOL 10000; MACROGOL 2000; MACROGOL 6000; NANOPARTICLE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; JEJUNUM MUCOSA; MALE; MEAN RESIDENCE TIME; NONHUMAN; RAT; SINGLE DRUG DOSE; SMALL INTESTINE MUCOSA; STOMACH MUCOSA;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; JEJUNUM; MALE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; PERMEABILITY; POLYANHYDRIDES; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SOLUBILITY; TIME FACTORS;

EID: 84863783683     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.04.001     Document Type: Article

References (49)

1. W.S. Fang, X.T. Liang, Recent progress in structure activity relationship and mechanistic studies of taxol analogues, Mini Rev. Med. Chem. 5 (2005) 1-12.
2. G. Samaranayake, K.A. Neidigh, D.G. Kingston, Modified taxols, 8. Deacylation and reacylation of baccatin III, J. Nat. Prod. 56 (1993) 884-898. (Pubitemid 23195617)
3. S.B. Horwitz, Mechanism of action of taxol, Trends Pharmacol. Sci. 13 (1992) 134-136.
4. J.A. Sparano, M. Wang, S. Martino, V. Jones, E.A. Perez, T. Saphner, A.C. Wolff, G.W. Sledge, W.C. Wood, N.E. Davidson, Weekly paclitaxel in the adjuvant treatment of breast cancer, New Engl. J. Med. 358 (2008) 1663-1671. (Pubitemid 351549913)
5. M. Montana, C. Ducros, P. Verhaeghe, T. Terme, P. Vanelle, P. Rathelot, Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers, J. Chemother. 23 (2011) 59-66.
6. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum, D.H. Johnson, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N. Engl. J. Med. 355 (2006) 2542-2550. (Pubitemid 44917502)
7. M. Zhan, W.Y. Tao, S.H. Pan, X.Y. Sun, H.C. Jiang, Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts, Anti-Cancer Drugs 20 (2009) 355-363.
8. P.S. Gill, A. Tulpule, B.M. Espina, S. Cabriales, J. Bresnahan, M. Ilaw, S. Louie, N.F. Gustafson, M.A. Brown, C. Orcutt, B. Winograd, D.T. Scadden, Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma, J. Clin. Oncol. 17 (1999) 1876-1883. (Pubitemid 29269260)
9. M.R. Wenk, A. Fahr, R. Reszka, J. Seelig, Paclitaxel partitioning into lipid bilayers, J. Pharm. Sci. 85 (1996) 228-231. (Pubitemid 26055806)
10. A.K. Singla, A. Garg, D. Aggarwal, Paclitaxel and its formulations, Int. J. Pharm. 235 (2002) 179-192. (Pubitemid 34185449)
11. J.S. Kloover, M.A. den Bakker, H. Gelderblom, J.P. van Meerbeeck, Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens, Br. J. Cancer 90 (2004) 304-305. (Pubitemid 38250619)
12. S.C. Kim, H.J. Yoon, J.W. Lee, J. Yu, E.-S. Park, S.C. Chi, Investigation of the release behaviour of DEHP from infusion sets by paclitaxel-loaded polymeric micelles, Int. J. Pharm. 293 (2005) 303-310. (Pubitemid 40381102)
13. C.D. Scripture, J. Szebeni, W.J. Loos, W.D. Figg, A. Sparreboom, Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of Taxol® and Paxene®, Cancer Biol. Ther. 4 (2005) 555-560. (Pubitemid 41351230)
14. C.M. Kruijtzer, J.H. Beijnen, J.H. Schellens, Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview, Oncologist 7 (2002) 516-530. (Pubitemid 36009000)
15. S. Peltier, J.M. Oger, F. Lagarce, W. Couet, J.P. Benoît, Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid Nanocapsules, Pharm. Res. 23 (2006) 1243-1250. (Pubitemid 43946146)
16. Y. Zhang, L.Z. Benet, The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein, Clin. Pharmacokinet. 40 (2001) 159-168. (Pubitemid 32324448)
17. L.E. Broker, S.A. Veltkamp, E.I. Heath, B.C. Kuenen, H. Gall, L. Astier, S. Parker, L. Kayitalire, P.M. Lorusso, J.H. Schellens, G. Giaccone, A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183, Clin. Cancer Res. 13 (2007) 3906-3912. (Pubitemid 47037598)
18. T.A. Brooks, H. Minderman, K.L. O'Loughlin, P. Pera, I. Ojima, M.R. Baer, R.J. Bernacki, Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein, Mol. Cancer Ther. 2 (2003) 1195-1205.
19. K.L. Hennenfent, R. Govindan, Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 17 (2006) 735-749.
20. M. Bayes, X. Rabasseda, J.R. Prous, Gateways to clinical trials, methods find, Exp. Clin. Pharmacol. 26 (2004) 53-84. (Pubitemid 38295512)
21. H. Li, M. Huo, J. Zhou, Y. Dai, Y. Deng, X. Shi, J. Massoud, Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N,O-hydroxyethyl chitosan micellar system, J. Pharm. Sci. 99 (2010) 4543-4553.
22. Z.S. Bavindir, N. Yuksel, Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery, J. Pharm. Sci. 99 (2010) 2049-2060.
23. G. Kim, S. Nie, Targeted cancer nanotherapy, Mater. Today 8 (2005) 28-33. (Pubitemid 41023878)
24. P. Gao, B.D. Rush, W.P. Pfund, T. Huang, J.M. Bauer, W. Morozowich, M.S. Kuo, M.J. Hageman, Development of a supersaturable SEDDS (S SEDDS) formulation of paclitaxel with improved oral bioavailability, J. Pharm. Sci. 92 (2003) 2386-2398. (Pubitemid 37484765)
25. S. Yang, R.N. Gursoy, G. Lambert, S. Benita, Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors, Pharm. Res. 21 (2004) 261-270. (Pubitemid 38221971)
26. B.D. Rege, J.P. Kao, J.E. Polli, Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers, Eur. J. Pharm. Sci. 16 (2002) 237-246.
27. K. Yoncheva, E. Lizarraga, J.M. Irache, Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties, Eur. J. Pharm. Sci. 24 (2005) 411-419. (Pubitemid 40387255)
28. E.D. Hugger, K.L. Audus, R.T. Borchardt, Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers, J. Pharm. Sci. 91 (2002) 1980-1990. (Pubitemid 36254934)
29. B.M. Johnson, W.N. Charman, C.J. Porter, An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine, AAPS PharmSci. 4 (2002) E40.
30. V. Zabaleta, M.A. Campanero, J.M. Irache, An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles, J. Pharm. Biomed. Anal. 44 (2007) 1072-1078. (Pubitemid 47239304)
31. P. Arbos, M.A. Arangoa, M.A. Campanero, J.M. Irache, Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles, Int. J. Pharm. 242 (2002) 129-136.
32. M. Agüeros, L. Ruiz-Gatón, C. Vauthier, K. Bouchemal, S. Espuelas, G. Ponchel, J.M. Irache, Combined hydroxypropyl-b-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel, Eur. J. Pharm. Sci. 38 (2009) 405-413.
33. I. Bravo-Osuna, C. Vauthier, H. Chacun, G. Ponchel, Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles, Eur. J. Pharm. Biopharm. 69 (2008) 436-444.
34. A.B. Dhanikula, R. Panchagnula, Localized paclitaxel delivery, Int. J. Pharm. 183 (1999) 85-100. (Pubitemid 29257954)
35. J.S. Woo, C.H. Lee, C.K. Shim, S.-J. Hwang, Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031, Pharm. Res. 20 (2003) 24-30. (Pubitemid 36152913)
36. S.W. Wang, J. Monagle, C. McNulty, D. Putnam, H. Chen, Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process, J. Pharm. Sci. 93 (2004) 2755-2767. (Pubitemid 39506626)
37. P.C. Mora, M. Cirri, S. Guenther, B. Allolio, F. Carli, P. Mura, Enhancement of dehydroepiandrosterone solubility and bioavailability by ternary complexation with alpha-cyclodextrin and glycine, J. Pharm. Sci. 92 (2003) 2177-2184. (Pubitemid 37356691)
38. M.H. Bartoli, M. Boitard, H. Fessi, H. Beriel, J.P. Devissaguet, F. Picot, F. Puisieux, In vitro and in vivo antitumoral activity of free, and encapsulated taxol, J. Microencapsul. 7 (1990) 191-197. (Pubitemid 20224139)
39. M.V. Varma, R. Panchagnula, Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo, Eur. J. Pharm. Sci. 25 (2005) 445-453. (Pubitemid 40853872)
40. R. Jain, S. Agarwal, S. Majumdar, X. Zhu, D. Pal, A.K. Mitra, Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification, Int. J. Pharm. 303 (2005) 8-19. (Pubitemid 41318017)
41. C.M. Kearns, L. Gianni, M.J. Egorin, Paclitaxel pharmacokinetics and pharmacodynamics, Semin. Oncol. 22 (1995) 16-23.
42. S. Khandavilli, R. Panchagnula, Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats, J. Invest. Dermatol. 127 (2007) 154-162. (Pubitemid 46005673)
43. T.K. Yeh, Z. Lu, M.G. Wientjes, J.L. Au, Formulating paclitaxel in nanoparticles alters its disposition, Pharm. Res. 22 (2005) 867-874. (Pubitemid 40898096)
44. M. Agüeros, V. Zabaleta, S. Espuelas, M.A. Campanero, J.M. Irache, Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles, J. Control. Release 145 (2010) 2-8.
45. J.M. Meerum Terwogt, M.M. Malingre, J.H. Beijnen, W.W. ten Bokkel Huinink, H. Rosing, F.J. Koopman, O. van Tellingen, M. Swart, J.H. Schellens, Coadministration of oral cyclosporin A enables oral therapy with paclitaxel, Clin. Cancer Res. 5 (1999) 3379-3384.
46. P. Arbós, M.A. Campanero, M.A. Arangoa, M.J. Renedo, J.M. Irache, Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties, J. Control. Release 89 (2003) 19-30. (Pubitemid 36412111)
47. K. Yoncheva, L. Guembe, M.A. Campanero, J.M. Irache, Evaluation of bioadhesive potential and intestinal transport of pegylated poly(anhydride) nanoparticles, Int. J. Pharm. 334 (2007) 156-165. (Pubitemid 46400309)
48. Y. Huang, W. Leobandung, A. Foss, N.A. Peppas, Molecular aspects of muco-and bioadhesion: tethered structures and site-specific surfaces, J. Control. Release 65 (2000) 63-71. (Pubitemid 30122916)
49. S.K. Lai, D.E. O'Hanlon, S. Harrold, S.T. Man, Y.-Y. Wang, R. Cone, J. Hanes, Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus, Proc. Natl. Acad. Sci. USA 104 (2007) 1482-1487. (Pubitemid 46214616)